Technical Analysis for BLCM - Bellicum Pharmaceuticals, Inc.
|Grade||Last Price||% Change||Price Change|
BLCM closed down 0.52 percent on Thursday, July 19, 2018, on 37 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
|Weak or Absent||Down||Down||Down|
|See historical BLCM trend table...|
|Date||Alert Name||Type||% Chg|
|Jul 19||Bollinger Band Squeeze||Range Contraction||0.00%|
|Jul 19||Narrow Range Bar||Range Contraction||0.00%|
|Jul 19||NR7||Range Contraction||0.00%|
|Jul 19||Inside Day||Range Contraction||0.00%|
|Jul 19||Down 3 Days in a Row||Weakness||0.00%|
|Jul 19||Down 4 Days in a Row||Weakness||0.00%|
|Jul 18||Bollinger Band Squeeze||Range Contraction||-0.52%|
|Jul 18||Down 3 Days in a Row||Weakness||-0.52%|
|Jul 17||Bollinger Band Squeeze||Range Contraction||-4.41%|
|Jul 17||Inside Day||Range Contraction||-4.41%|
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of various forms of cancer. Its lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Its preclinical product candidates include BPX-401, a chimeric antigen receptor (CAR-T) product candidate for the treatment of hematological cancers that express the CD19 antigen; BPX-601, a CAR-T product candidate for treating solid tumors overexpressing the prostate stem cell antigen; and BPX-701, a TCR product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is based in Houston, Texas.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more BLCM news...
|52 Week High||13.3|
|52 Week Low||5.02|
|200-Day Moving Average||8.3486|
|50-Day Moving Average||8.2014|
|20-Day Moving Average||7.921|
|10-Day Moving Average||8.043|
|Average True Range||0.3949|
|Chandelier Exit (Long, 3 ATRs )||7.9153|
|Chandelier Exit (Short, 3 ATRs )||8.4747|
|Upper Bollinger Band||8.4532|
|Lower Bollinger Band||7.3888|
|Percent B (%b)||0.18|
|MACD Signal Line||-0.0651|
|Market Cap||251.85 Million|
|Num Shares||33.2 Million|
|Price-to-Earnings (P/E) Ratio||-2.58|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||7.87|
|Resistance 3 (R3)||7.86||7.77||7.82|
|Resistance 2 (R2)||7.77||7.69||7.77||7.80|
|Resistance 1 (R1)||7.67||7.65||7.63||7.68||7.79|
|Support 1 (S1)||7.48||7.50||7.44||7.49||7.37|
|Support 2 (S2)||7.39||7.46||7.39||7.36|
|Support 3 (S3)||7.29||7.39||7.34|
|Support 4 (S4)||7.30|